Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines

F. Nolè, L. Biganzoli, R. Buzzoni, E. Bajetta

Research output: Contribution to journalArticlepeer-review

Abstract

The activity of carboplatin (CBDCA) was tested in 21 consecutive patients with advanced colorectal cancer that had progressed during fluoropyrimidine therapy. CBDCA was chosen in view of the favourable results obtained in previous phase II studies. We were unable to find any activity of the agent which was given every 21 days at a dose of 400 mg/m2. The main toxicity was haematological. CBDCA is not recommended in pretreated patients with colorectal cancer.

Original languageEnglish
Pages (from-to)1330-1331
Number of pages2
JournalEuropean Journal of Cancer
Volume29
Issue number9
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines'. Together they form a unique fingerprint.

Cite this